Publications by the researcher in collaboration with José de León (36)

2026

  1. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase

    The American Journal of Geriatric Psychiatry, Vol. 34, Núm. 4, pp. 591-601

  2. A Systematic Review and a VigiBase Study of Accidental Clozapine Intoxications in Children and Adolescents

    Human Psychopharmacology, Vol. 41, Núm. 5

  3. A study in VigiBase of clozapine fatal outcomes in 7874 middle-aged versus 4380 young adults

    Psychiatry Research, Vol. 359, pp. 117037

  4. An international adult guideline for making Clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and Clozapine levels

    Chinese Journal of Psychiatry, Vol. 59, Núm. 2, pp. 87-113

  5. Changing your perspective on fatal outcomes in clozapine-treated patients. They do not die of agranulocytosis

    Asian Journal of Psychiatry

  6. Clozapine and Suicide in VigiBase: Most Important Fatal Outcome in Young Males and Differences Between Attempted and Completed Suicide

    Journal of clinical psychopharmacology, Vol. 46, Núm. 1, pp. 5-15

  7. Comparative Pharmacovigilance Analysis of Pulmonary Embolism Across Antipsychotics in VigiBase

    Journal of Clinical Psychopharmacology, Vol. 46, Núm. 5, pp. 589-597

  8. Reply to beyond fatality signals: Reconsidering clozapine safety through severe gastrointestinal hypomotility and real-world clinical complexity

    Asian Journal of Psychiatry

  9. Reply to “Beyond Hypersalivation: Protecting Older Clozapine Users through Better Recognition of Swallowing Vulnerability”

    American Journal of Geriatric Psychiatry

  10. VigiBase suggests that the number of deaths by suicide in adolescents with schizophrenia as a result of not taking clozapine may be much higher than the number of deaths from agranulocytosis after taking clozapine

    European Child and Adolescent Psychiatry

2025

  1. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety, Vol. 24, Núm. 11, pp. 1301-1311

  2. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts: Clozapine Croatia suicide

    Psychiatry Research, Vol. 347

  3. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature

    Expert Opinion on Drug Safety

  4. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

    European Child and Adolescent Psychiatry, Vol. 34, Núm. 7, pp. 2083-2091

  5. Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men

    Journal of clinical psychopharmacology, Vol. 45, Núm. 6, pp. 547-553

  6. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I A Review of the Pharmacokinetic Literature and Proposed Changes

    Journal of Clinical Psychopharmacology, Vol. 45, Núm. 3, pp. 179-196

  7. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A review of fatal outcomes in US Pharmacovigilance data and proposed changes

    Journal of Clinical Psychopharmacology

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  3. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 60-65